Article
Chemistry, Multidisciplinary
Yan Zou, Yibin Wang, Sen Xu, Yanjie Liu, Jinlong Yin, David B. Lovejoy, Meng Zheng, Xing-Jie Liang, Jong Bae Park, Yuri M. Efremov, Ilya Ulasovand, Bingyang Shi
Summary: A new type of GBM-cell membrane camouflaged and pH-sensitive biomimetic nanoparticles have been developed for combined TMZ and CDDP therapy for GBM. The results show that these nanoparticles can efficiently transport drugs across the blood-brain barrier and specifically target GBM, allowing for controlled release at GBM sites and demonstrating potent anti-GBM effects without obvious side effects.
ADVANCED MATERIALS
(2022)
Article
Cell Biology
Xiao-Ning Zhang, Kai-Di Yang, Cong Chen, Zhi-Cheng He, Qiang-Hu Wang, Hua Feng, Sheng-Qing Lv, Yan Wang, Min Mao, Qing Liu, Yao-Yao Tan, Wen-Ying Wang, Tian-Ran Li, Lin-Rong Che, Zhong-Yi Qin, Ling-Xiang Wu, Min Luo, Chun-Hua Luo, Yu-Qi Liu, Wen Yin, Chao Wang, Hai-Tao Guo, Qing-Rui Li, Bin Wang, Wei Chen, Shuang Wang, Yu Shi, Xiu-Wu Bian, Yi-Fang Ping
Summary: The study reveals the role of pericytes in potentiating DDR signaling in GBM cells, and suggests that targeting CCL5-CCR5 signaling could be an effective therapeutic strategy to improve chemotherapeutic efficacy against GBM.
Article
Oncology
Jingjing Ge, Cheng Li, Fengjun Xue, Shaopei Qi, Zhimeng Gao, Chunjiang Yu, Junping Zhang
Summary: The combination of apatinib and temozolomide shows efficacy in treating recurrent glioblastoma with manageable toxicities. It can be considered as a salvage therapy for patients who have not responded well to other treatments.
FRONTIERS IN ONCOLOGY
(2021)
Editorial Material
Biochemistry & Molecular Biology
Kirit Singh, Kelly M. Hotchkiss, Ian F. Parney, John De Groot, Solmaz Sahebjam, Nader Sanai, Michael Platten, Evanthia Galanis, Michael Lim, Patrick Y. Wen, Giuseppe Minniti, Howard Colman, Timothy F. Cloughesy, Minesh P. Mehta, Marjolein Geurts, Isabel Arrillaga-Romany, Annick Desjardins, Kirk Tanner, Susan Short, David Arons, Elizabeth Duke, Wolfgang Wick, Stephen J. Bagley, David M. Ashley, Priya Kumthekar, Roel Verhaak, Anthony J. Chalmers, Anoop P. Patel, Colin Watts, Peter E. Fecci, Tracy T. Batchelor, Michael Weller, Michael A. Vogelbaum, Matthias Preusser, Mitchel S. Berger, Mustafa Khasraw
Summary: A breakthrough in drug discovery for glioblastoma necessitates the consecutive collection of central nervous system tissue through window of opportunity trials.
Article
Medicine, Research & Experimental
Yuan Yuan Cheng, Xue Yang, Xin Gao, Si Xin Song, Ming Feng Yang, Fang Min Xie
Summary: LGR6 promotes malignancy and chemoresistance in GBM, potentially through activation of the Akt signaling pathway.
EXPERIMENTAL AND THERAPEUTIC MEDICINE
(2021)
Article
Multidisciplinary Sciences
Andrew J. Brenner, John Floyd, Lisa Fichtel, Joel Michalek, Kunal P. Kanakia, Shiliang Huang, David Reardon, Patrick Y. Wen, Eudocia Quant Lee
Summary: The study investigated the safety and efficacy of Evo in combination with bevacizumab for treating bevacizumab refractory glioblastoma patients. Results showed a median overall survival of approximately 4.6 months with a median time to disease progression of 53 days from best response. The progression free survival at 4 months (PFS-4) on Evo-Bev treatment demonstrated a statistically significant improvement.
SCIENTIFIC REPORTS
(2021)
Article
Multidisciplinary Sciences
Edikan A. Ogunnaike, Alain Valdivia, Mostafa Yazdimamaghani, Ernesto Leon, Seema Nandi, Hannah Hudson, Hongwei Du, Simon Khagi, Zhen Gu, Barbara Savoldo, Frances S. Ligler, Shawn Hingtgen, Gianpietro Dotti
Summary: The delivery of CAR-T cells within the surgical cavity using a fibrin-based gel demonstrates superior antitumor activity compared to direct inoculation into the tumor resection cavity in a model of subtotal glioblastoma resection.
Article
Oncology
Youri Hoogstrate, Kaspar Draaisma, Santoesha A. Ghisai, Levi van Hijfte, Nastaran Barin, Iris de Heer, Wouter Coppieters, Thierry P. P. van den Bosch, Anne Bolleboom, Zhenyu Gao, Arnaud J. P. E. Vincent, Latifa Karim, Manon Deckers, Martin J. B. Taphoorn, Melissa Kerkhof, Astrid Weyerbrock, Marc Sanson, Ann Hoeben, Slavka Lukacova, Giuseppe Lombardi, Sieger Leenstra, Monique Hanse, Ruth E. M. Fleischeuer, Colin Watts, Nicos Angelopoulos, Thierry Gorlia, Vassilis Golfinopoulos, Vincent Bours, Martin J. van den Bent, Pierre A. Robe, Pim J. French
Summary: A better understanding of the transcriptional evolution of IDH-wild-type glioblastoma is crucial for optimizing treatment. Through RNA sequencing, this study demonstrates that glioblastomas mainly evolve through microenvironmental reorganization rather than molecular evolution of tumor cells. The changes in tumor composition over time, including alterations in neuron and oligodendrocyte marker genes and an increase in tumor-associated macrophages, are confirmed by single-cell RNA-seq and immunohistochemistry.
Review
Biochemistry & Molecular Biology
Karoline Almeida Lima, Isabeli Yumi Araujo Osawa, Maria Carolina Clares Ramalho, Izadora de Souza, Camila Banca Guedes, Claudio Henrique Dahne de Souza Filho, Linda Karolynne Seregni Monteiro, Marcela Teatin Latancia, Clarissa Ribeiro Reily Rocha
Summary: This article highlights the constitutive activation of NRF2 in glioblastoma and its role in promoting survival and protecting against TMZ resistance through various molecular pathways. It also discusses potential strategies for targeting NRF2 as an adjuvant therapy and the importance of identifying NRF2 modulators for therapeutic intervention.
Article
Oncology
Maria del Mar Alvarez-Torres, Elies Fuster-Garcia, Carmen Balana, Josep Puig, Juan M. Garcia-Gomez
Summary: Despite comprehensive treatment with surgery, chemotherapy, and radiotherapy, glioblastoma patients still face a poor prognosis. Extending adjuvant chemotherapy may benefit patients with moderate vascularity and methylated MGMT, but does not show benefits for highly vascular tumors, even in the presence of MGMT methylation.
Article
Oncology
A. Bosio, G. Cerretti, M. Padovan, M. Caccese, L. Denaro, F. Chioffi, A. Della Puppa, V. Aldegheri, V. Guarneri, V. Zagonel, G. Lombardi
Summary: The aim of this study was to evaluate the efficacy and safety of metronomic temozolomide (TMZ) in patients with recurrent glioblastoma (GBM). The results showed that rechallenge with metronomic TMZ is a well-tolerated option for the treatment of recurrent GBM.
Article
Pharmacology & Pharmacy
Sadia Nasir, Sadia Nazir, Rumeza Hanif, Aneela Javed
Summary: This study utilized solid lipid nanoparticles (SLNPs) for targeted delivery of temozolomide (TMZ) against glioblastoma multiforme (GBM). Both in-vitro and in-vivo experiments showed that SLNP-TMZ had higher cytotoxicity and inhibitory effect on cell migration compared to free TMZ. The expression of inflammatory markers was also significantly elevated in resistant cell lines and mouse models, indicating the potential application of SLNP-TMZ for both TMZ-sensitive and resistant GBM therapy.
Article
Nanoscience & Nanotechnology
Ke Du, Qiuyu Xia, Jian Sun, Fude Feng
Summary: A strategy to cage MTIC by N-acylation of the triazene moiety was introduced to boost MTIC stability. A diblock copolymer-based MTIC prodrug installed with a disulfide linkage was designed for self-assembled polymer micelles that could release MTIC through stimuli factors such as glutathione (GSH) and visible light irradiation. The microenvironment-responsive polymeric micelles showed benefits in suppressing both TMZ-sensitive and TMZ-resistant GBM cells, providing a new option for glioma treatment based on TMZ.
ACS APPLIED MATERIALS & INTERFACES
(2021)
Article
Cell Biology
Priya Kumthekar, Caroline H. Ko, Tatjana Paunesku, Karan Dixit, Adam M. Sonabend, Orin Bloch, Matthew Tate, Margaret Schwartz, Laura Zuckerman, Ray Lezon, Rimas Lukas, Borko Jovanovic, Kathleen McCortney, Howard Colman, Si Chen, Barry Lai, Olga Antipova, Junjing Deng, Luxi Li, Serena Tommasini-Ghelfi, Lisa A. Hurley, Dusten Unruh, Nitya Sharma, Manoj Kandpal, Fotini M. Kouri, Ramana Davuluri, Daniel J. Brat, Miguel Muzzio, Mitchell Glass, Vinod Vijayakumar, Jeremy Heidel, Francis J. Giles, Ann K. Adams, C. David James, Gayle E. Woloschak, Craig Horbinski, Alexander H. Stegh
Summary: The research team has developed a novel treatment approach for GBM using SNAs for precision medicine treatment, which has shown potential in clinical trials.
SCIENCE TRANSLATIONAL MEDICINE
(2021)
Article
Oncology
Maaike Y. Kapteijn, Shanna Zwaan, Esther ter Linden, El Houari Laghmani, Rob F. P. van den Akker, Araci M. R. Rondon, Sabina Y. van der Zanden, Jacques Neefjes, Henri H. Versteeg, Jeroen T. Buijs
Summary: This study found a promoting role of the commonly used chemotherapeutic agents Temozolomide and Lomustine on tissue factor (TF) procoagulant activity and gene/protein expression in glioblastoma (GBM) cell lines. This may explain the increased risk of thrombosis in GBM patients undergoing chemotherapy. Therefore, GBM patients with high TF levels may benefit from anticoagulant treatment to decrease the risk of chemotherapy-induced thrombosis.